Quick Answer
Bluejay Diagnostics, Inc. reported R&D Expense of $3.05 million for fiscal year 2025.
Bluejay Diagnostics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.05M | -12.2% |
| 2024 | $3.47M | -39.2% |
| 2023 | $5.71M | +37.6% |
| 2022 | $4.15M | +261.7% |
| 2021 | $1.15M | +117.7% |
| 2020 | $527.3K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $785.6K | +42.4% | -11.7% |
| June 30, 2025 | $889.9K | -13.8% | +13.4% |
| March 31, 2025 | $784.8K | -41.2% | +42.3% |
| September 30, 2024 | $551.7K | -60.5% | -46.6% |
| June 30, 2024 | $1.03M | -38.4% | -22.6% |
| March 31, 2024 | $1.33M | -1.5% | -4.5% |
| September 30, 2023 | $1.40M | +1.3% | -16.6% |
| June 30, 2023 | $1.68M | +121.6% | +23.8% |
- Bluejay Diagnostics, Inc. showed a decrease of -12.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Bluejay Diagnostics, Inc.’s r&d expense has grown by 477.8% (from $527.3 thousand to $3.05 million).
- The most recent figure is from Bluejay Diagnostics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: